EMA Recommends Extension of Indications for Durvalumab to Include Treatment of Patients with Resectable NSCLC at High Risk of Recurrence By Ogkologos - March 28, 2025 944 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns neoadjuvant and adjuvant treatment of patients with resectable non-small cell lung cancer Source RELATED ARTICLESMORE FROM AUTHOR Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Relacorilant Annual Multicancer Early Detection Test Not Associated with a Lower Incidence Rate of Stage III or IV Cancer After Three Screening Rounds and 12... MOST POPULAR First-Line Treatment with Pembrolizumab-Chemotherapy Results in Longer OS than Chemotherapy Alone... July 26, 2022 Combination Chemo Helps People with Leiomyosarcoma Live Longer October 2, 2024 Abnormal Results from Prenatal Blood Test Could Point to Cancer in... February 21, 2025 “Things Are Shrinking” Says Olivia Newton-John About Her Stage IV Breast... February 18, 2020 Load more HOT NEWS Fatiga relacionada con el cáncer: Lo que las personas con cáncer... A urine test for bladder cancer: What’s the latest? Woman Who Lost Husband to Male Breast Cancer Goes on Road... Farmer With Stage IV Cancer Is Too Sick To Harvest Crops...
